All In Biotech

Drug Trial Radar · NCT04064060

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

665

Planned (sponsor's estimate)

Start

Aug 12, 2019

Primary completion

May 12, 2028

Study completion May 12, 2028

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept * Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met * The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Participants will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase * Transition Phase is defined as one Enrollment visit * Treatment Phase: For participants in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. This does not apply to participants that are in long-term follow-up from the parent protocol * Follow-up Phase includes: \- 42 Day Safety Follow-up Visit * During the Safety Follow up, the participants will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting \- Long-term Post-treatment Follow-up (LTPTFU) Phase * Participants will be followed for overall survival every 6 months for at least 5 years from first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later, or until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Participants will also be monitored for progression to AML or any malignancies/pre-malignancies. New anticancer or disease related therapies should be collected at the same time schedule Participants transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study. The ACE-536-LTFU-001 rollover study will be terminated, and relevant participants will discontinue from the study when all participants fulfill 5 years on the study, including treatment and follow-up.

Conditions

  • Myelodysplastic Syndromes (MDS)
  • Beta-thalassemia
  • Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

Interventions

  • LuspaterceptDrug

    Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: From enrollment until at least 42 Day Safety Follow-up Phase
  2. Number of participants progressing to high/very high risk MDS or AML.Time frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
  3. Percentage of participants progressing to high/very high risk MDS or AMLTime frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
  4. Number of participants developing other malignancies/pre-malignanciesTime frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)
  5. Percentage of participants developing other malignancies/pre-malignanciesTime frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years)

Locations

143 sites in 22 countries. Site status is shown where the registry gives one.

  • Local Institution - 968

    Los Angeles, California · Completed

  • Local Institution - 971

    Oakland, California · Completed

  • Local Institution - 978

    Stanford, California · Completed

  • Local Institution - 975

    Tampa, Florida · Completed

  • Local Institution - 970

    Chicago, Illinois · Completed

  • Local Institution - 973

    Boston, Massachusetts · Completed

  • Local Institution - 961

    Detroit, Michigan · Completed

  • Local Institution - 969

    New York, New York · Completed

  • Local Institution - 967

    Cleveland, Ohio · Completed

  • Local Institution - 972

    Philadelphia, Pennsylvania · Completed

  • Vanderbilt - Ingram Cancer Center

    Nashville, Tennessee · Withdrawn

  • The University of Texas - MD Anderson Cancer Center

    Houston, Texas · Withdrawn

  • Royal Prince Alfred Hospital

    Camperdown, Australia · Recruiting

  • Local Institution - 100

    South Brisbane, Queensland, Australia · Completed

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Local Institution - 102

    Clayton, Victoria, Australia · Completed

  • Local Institution - 182

    Brasschaat, Belgium · Completed

  • Local Institution - 180

    Bruges, Belgium · Completed

  • Local Institution - 183

    Ghent, Belgium · Completed

  • Local Institution - 184

    Leuven, Belgium · Completed

  • Local Institution - 221

    Plovdiv, Bulgaria · Completed

  • Local Institution - 220

    Boulevard, Sofia, Bulgaria · Completed

  • Local Institution - 262

    Toronto, Ontario, Canada · Completed

  • Local Institution - 260

    Toronto, Ontario, Canada · Completed

  • Local Institution - 263

    Toronto, Ontario, Canada · Completed

  • Local Institution - 131

    Beijing, Beijing Municipality, China · Withdrawn

  • Local Institution - 135

    Guangzhou, Guangdong, China · Withdrawn

  • Local Institution - 132

    Shanghai, Shanghai Municipality, China · Withdrawn

  • Local Institution - 134

    Chengdu, Sichuan, China · Withdrawn

  • Local Institution - 130

    Tianjin, Tianjin Municipality, China · Withdrawn

  • Local Institution - 133

    Hangzhou, Zhejiang, China · Withdrawn

  • Local Institution - 305

    Angers, France · Completed

  • Local Institution - 300

    Créteil, France · Completed

  • Local Institution - 310

    La Tronche, France · Completed

  • Local Institution - 306

    Lille, France · Completed

  • Local Institution - 301

    Marseille, France · Completed

  • Local Institution - 302

    Paris, France · Completed

  • Local Institution - 307

    Pessac, France · Withdrawn

  • Local Institution - 304

    Pierre-Bénite, France · Completed

  • Local Institution - 308

    Strasbourg, France · Completed

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.